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The administration of thrombolytic therapy is a time-critical 
intervention that in South Africa was until recently limited 
to administration in coronary care units and some casualty 
departments.  This approach can lead to significant treatment 
delay, particularly for rural/urban-rural patients, where inter-
hospital transfers can be prolonged.
HPCSA decision on thrombolysis
The Health Professions Council of South Africa (HPCSA) 
Professional Board for Emergency Care Practitioners recently 
introduced thrombolysis as a new skill for use by emergency 
medical care graduates as part of a structured research 
programme supervised by the Durban Institute of Technology. 
The aim of this research project will be to inform and guide 
the roll-out of pre-hospital thrombolysis to all South African 
paramedics.
   The introduction of pre-hospital thrombolysis will 
see a significant improvement in the management of ST 
elevation myocardial infarction (STEMI), and the associated 
additional education/decision-making process will impact 
on the remaining cardiac patients who are not suitable for 
thrombolysis.
   Thrombolysis, or more correctly fibrinolysis, is a process 
that speeds up the body’s own ability to remove coronary 
artery clots, thereby improving myocardial blood flow. The 
single biggest hurdle in the provision of reperfusion therapy is 
prolonged time to treatment. Each minute of delay in treatment 
results in a loss of 11 days of life for the patient.1 Prompt 
provision of thrombolysis has therefore been compared to the 
urgency required for successful defibrillation.
   Although patients2 are responsible for the greatest overall 
delay in obtaining treatment, the impact of system delays can 
also be significant as transfer to hospital can be prolonged and 
not all casualty departments offer thrombolytic therapy. This 
is not the case internationally, where it has become part of pre-
hospital treatment.3
   Internationally pre-hospital thrombolysis by non-physicians 
is recommended in all systems that cannot ensure that 
patients will be in hospital within 60 minutes of contacting the 
emergency services.3 A similar time target set in South Africa 
would place the administration of thrombolytic therapy firmly 
in the domain of the paramedic. The shift towards earlier 
administration of thrombolytic therapy is based on strong 
clinical evidence of patient benefit.1,4-5
   The time saved with the introduction of pre-hospital 
thrombolysis can range from < 33 minutes4 to > 130 minutes1 
depending on local emergency medical service (EMS) systems, 
hospital setup and transfer times. It is arguable that within the 
context of South African EMS we should be able to emulate 
and surpass the benefits demonstrated by the GREAT study,1 
which is currently the benchmark study for improving patient 
outcomes.
Research project on the initiation of 
thrombolysis
Paramedics in South African EMS can obtain registration 
with the HPCSA as advanced life support (ALS) practitioners 
on successful completion of either a short in-service course 
or a 3-year/4-year degree programme.6 Currently practice 
of thrombolytic therapy is limited to paramedics who 
have completed additional study to obtain a 4-year degree 
in emergency medical care. A key aspect of the 4-year 
qualification is decision making, and this is reflected in the 
lack of strict protocol for delivery of thrombolytic therapy. The 
rationale for the lack of strict protocol is to develop evidence-
based medicine and autonomous paramedic practitioners. This 
is currently not the case in other countries that have introduced 
pre-hospital thrombolysis within a strict framework.7 
   The key purpose of the research project is to determine how 
to implement pre-hospital thrombolysis fully within South 
African emergency EMS. Numerous avenues exist, but a tiered 
system with autonomous paramedic practitioners at one end 
supported by protocol-driven thrombolysis by other ALS 
providers may be the first step in the wider introduction of 
pre-hospital thrombolysis.
   To ensure autonomous practice at a higher degree of clinical 
decision making is essential, as thrombolysis is not appropriate 
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in all cases of myocardial infarction, and despite its mortality 
benefits thrombolysis is not a benign therapy. 
   Thrombolysis is associated with a number of significant side-
effects, including a 1% risk of fatal intracranial haemorrhage8,9 
and an accelerated risk of cardiac rupture among certain 
patient subgroups.10 However, with the exception of cardiac 
rupture all potential side-effects remain static with time, but 
clinical benefit is greatly affected by treatment delay.1,10
   The safe autonomous administration of thrombolytic therapy 
therefore requires the paramedic to ‘risk stratify’ patients while 
developing additional assessment skills such as interpretation 
of the 12-lead electrocardiogram (ECG) and use of additional 
ECG lead placement to diagnose isolated posterior or right 
ventricular infarcts. 
   Examples of the degree of decision-making skill required 
would be deciding whether an elderly hypertensive woman 
(< 50 kg in weight) with an inferior infarct, who is between 
10 and 12 hours post infarct, will benefit from thrombolysis,10 
or deciphering whether left bundle-branch block is a new or 
chronic ECG change. It is clear that thrombolysis in the South 
African context cannot rely on simple ECG pattern-recognition 
protocols used elsewhere.
   In addition to the administration of thrombolytic therapy 
the practitioner needs to learn to challenge previously held 
beliefs, particularly regarding the prophylactic treatment of 
cardiac arrhythmias such as R-on-T phenomena and frequent 
ventricular ectopics, especially after thrombolysis.  The routine 
treatment of these arrhythmias provides no mortality benefits 
and can result in potentially drug-induced side-effects such as 
hypotension, AV node block and drug toxicity.11,12 
   Thrombolysis is only appropriate for a relatively small 
number of patients with an acute coronary syndrome, but all 
paramedics need to consider the vital importance of treating 
pain and the appropriate management of arrhythmias.3,13 
Paramedics should also encourage their colleagues at basic 
and intermediate level to use Entonox as pain relief in cardiac 
patients and to summon ALS assistance as soon as possible. 
   Continued early use of aspirin is of vital importance. 
Some studies have shown significant mortality benefits with 
aspirin use, similar to the benefits with thrombolysis,14,15 but 
internationally aspirin tends to be underadministered by ALS 
personnel.16 The wider use of aspirin by all EMS personnel 
should be encouraged and supported, as aspirin use has few 
contraindications and is highly effective in reducing cardiac 
mortality in all patients, not just those with STEMI.
Primary coronary intervention (PCI) 
versus thrombolysis
There is great debate regarding thrombolysis versus PCI.17,18 It 
has been argued that there is less time pressure when choosing 
PCI over thrombolysis;18 this resulted in numerous trials in 
which thrombolysis was withheld and the patient transferred 
for PCI.19,20 De Luca and colleagues21 recently challenged this 
approach by demonstrating that total ‘ischaemic time’ affects 
mortality and that for every 30-minute delay before performing 
PCI mortality increases by 7.5%. 
   In their study Widimsky et al.19 recommended thrombolysis 
if patients present within 3 hours of symptom commencement. 
The evidence from Steg et al.,20 based on prehospital 
thrombolysis, clearly demonstrated a mortality benefit for 
thrombolytic therapy if administered less than 2 hours from the 
onset of symptoms when directly compared with PCI. 
   It is appropriate to highlight that clinical trials comparing 
thrombolysis with PCI have a number of issues that need to 
be considered. Brophy and Bogaty17 highlighted a number 
of these, such as inclusion bias, prolonged in-hospital 
delays before initiating thrombolysis, comparison of PCI 
with streptokinase and not with fibrin-specific agents, and 
exceptional door-to-balloon times during clinical trials. 
   The USA’s National Registry of Myocardial Infarction 
(NRMI) project recently demonstrated that the benefits of 
PCI over fibrin-specific agents disappear if PCI takes longer 
than 69 minutes.22 This potentially represents the time taken 
to reperfuse an occluded artery using thrombolytic therapy.23 
When we consider the evidence presented by Pinto22 and 
by Nallamothu et al.,24 who highlighted that less than 5% 
of patients (entered into the NRMI) experiencing a STEMI 
achieved a door-to-balloon-time of 90 minutes, we perhaps 
need to consider again the role of prompt thrombolysis.
So what’s the role for PCI?
Increasingly the specific role of PCI will be as a ‘rescue’ therapy 
for failed reperfusion,20,25,26 treatment of high-risk patients in 
cardiogenic shock,27 and treatment of patients with significant 
contraindications to thrombolysis.17 However, an increasingly 
important role of early PCI could be within the field of 
facilitated PCI following thrombolysis.26,28
Facilitated PCI 
Facilitated PCI involves the use of early thrombolysis 
supported by early PCI, typically within the first 24 hours. The 
GRACIA-1 and GRACIA-2 trials26,28 using glycoprotein IIa/IIIb 
inhibitors and stent have demonstrated this approach to be 
safe and clinically effective. GRACIA-228 recently demonstrated 
that 61% of patients receiving thrombolysis (tenecteplase) 
supported by facilitated PCI had total resolution of ST 
elevation at 6 hours compared with 41% of patients receiving 
PCI only. 
Conclusion
South African paramedics are entering an exciting time and 
need to grasp the mantle of evidence-based pre-hospital 
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cardiac care. The introduction of pre-hospital thrombolysis 
plus the supporting education that underpins this extension 
of patient management should have a far-reaching clinical 
impact. Of equal importance are the clinical benefits that earlier 
pre-hospital thrombolysis will offer patients, particularly if 
supported by early angiographic intervention.
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